Report Overview

The EU Ankylosing Spondylitis Market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Ankylosing spondylitis is a systemic inflammatory disease that primarily affects the spine. In ankylosing spondylitis, the joints, ligaments, and spine become inflamed. The inflammation leads to pain and stiffness in the lower back of the body and progress into the upper spine, neck, and chest. The joints and bones (vertebrae) fuse together eventually, causing the spine to become rigid and inflexible. Fused spine is called as bamboo spine as it is identified on X-rays. Other joints such as the hips, ribs, and small joints of hands and feet are also affected



Market Drivers

Based on ankylosing spondylitis market drivers and restraints, the patent expiry of blockbuster products restrains the market growth. In October 2018, the patent of AbbVies proprietary product Humira expired in the EU. Furthermore, the EU patent of Enbrel (Amgen Inc./Pfizer Inc.) and Remicade (Johnson & Johnson Services, Inc./Merck & Co., Inc.) expired. For the expansion of market, the market is expected to expand in the near future because of increase in research and development expenditure, rise in the number of treatment seeking population, and high unmet needs of current treatment in terms of appropriate drugs